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Abstract 
Background: To compare a near decade of follow-up, newer control cohort data, use of both the societal and third 
party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and 
cost-effectiveness of intravitreal ranibizumab therapy for neovascular, age-related macular degeneration (AMD).
Methods: Value-Based Medicine®, 12-year, combined-eye model, cost-utility analysis employing MARINA and HORI-
ZON clinical trial data. Preference-based comparative effectiveness outcomes were quantified in (1) QALY (quality-
adjusted life-year) gain, and (2) percent improvement in quality-of-life, while cost-effectiveness outcomes were 
quantified in (3) the cost-utility ratio (CUR) and financial return-on-investment (ROI) to society.
Results: Using MARINA and HORIZON trial data and a meta-analysis control cohort after 24 months, ranibizumab 
therapy conferred a combined-eye patient value (quality-of-life) gain of 16.3%, versus 10.4% found in 2006. The two-
year direct ophthalmic medical cost for ranibizumab therapy was $46,450, a 33.8% real dollar decrease from 2006. The 
societal cost perspective CUR was −$242,920/QALY, indicating a $282,517 financial return-on-investment (ROI), or 
12.3%/year to society for direct ophthalmic medical costs expended. The 3rd party insurer CUR ranged from $21,199/
QALY utilizing all direct, medical costs, to $69,591/QALY using direct ophthalmic medical costs.
Conclusions: Ranibizumab therapy for neovascular AMD in 2015, considering treatment of both eyes, conferred 
greater patient value gain (comparative effectiveness) and improved cost-effectiveness than in 2006, as well as a large 
monetary return-on-investment to the Gross Domestic Product and nation’s wealth. The model herein integrates 
important novel features for neovascular age-related macular degeneration, vitreoretinal cost effectiveness analyses, 
including: (1) treatment of both eyes, (2) a long-term, untreated control cohort, and (3) the use of societal costs.
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Background
Intravitreal ranibizumab therapy has been shown to be an 
effective treatment for minimally classic/occult [1, 2] and 
classic [3] subfoveal choroidal neovascularization occur-
ring with neovascular age-related macular degeneration 
(NVAMD) in well designed and executed Level 1 [4] 
clinical trials. Ranibizumab (Lucentis®) is a recombinant 
humanized, IgG1 kappa isotype, monoclonal antibody 
fragment designed for intraocular use [5]. It binds to and 
inhibits the biologic activity of human vascular endothe-
lial growth factor A (VEGF-A), a molecule believed to be 
primarily responsible for the development of the choroi-
dal neovascularization associated with NVAMD.
A number of healthcare economic studies, including 
cost-utility analyses, cost-effectiveness analyses and cost-
benefit analyses, have addressed the use of ranibizumab 
for the treatment of NVAMD [6–12]. Unfortunately, even 
with sensitivity analyses [13], very few cost-utility analy-
ses (also called cost-effectiveness analyses by some [13]) 
are comparable due to the use of different utilities, dis-
similar utility respondents, differing cost perspectives, 
diverse costs bases, unlike discounting and so forth [14]. 
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The Center for Value-Based Medicine® has estimated 
that over 27,000,000 different, input variable combina-
tions can be used in a single cost-utility analysis [4]. Even 
one different input can make a major difference in the 
outcome [4, 14].
Value-Based Medicine® (VBM) [4, 14–17] is a meth-
odology of cost-utility analysis employing standardized 
inputs to determine the patient value gain and financial 
value gain conferred by healthcare interventions. Patient 
value gain is quantified by improvement in length-of-life 
and/or quality-of-life; it is measured in QALY (quality-
adjusted life-year) gain and percent patient value gain. 
The intervention which confers the greatest patient value 
has the greatest comparative effectiveness. VBM inte-
grates financial value gain using the resources expended 
for the patient value gain in terms of the cost-utility 
ratio ($/QALY, or dollars expended per QALY gained), 
and the dollar return-on-investment (ROI) to society for 
the interventional, direct medical costs expended (cost-
benefit ratio). VBM [4, 14–17] standardizes cost-utility 
analysis variables by typically utilizing: (1) time tradeoff 
utilities, (2) patient utility respondents, (3) the average 
national Medicare Fee Schedule, and (4) both societal 
and 3rd party insurer cost perspectives.
The Panel on Cost-Effectiveness in Health and Medi-
cine [13, 18] has recommended that cost-utility analyses 
use the societal cost perspective. While the literature is 
replete with cost-utility analyses touting the cost-effec-
tiveness of healthcare interventions, most do not address 
the entirety of societal costs affected by healthcare inter-
ventions [14].
Beauchamp and colleagues [19] have long advocated 
that medicine’s business is the production of patient 
value and economic return. We agree that healthcare 
economic analyses should ideally provide accurate 
assessments of, not only conferred patient value and the 
societal cost-utility, but also the financial ROI accrued to 
society and to the GDP (Gross Domestic Product) [14].
In 2008, we published a third party insurer, second-eye 
model, cost-utility analysis (using 2006 data and costs) 
on ranibizumab for the treatment of neovascular AMD 
utilizing MARINA (Minimally classic/occult trial of the 
Anti-VEGF antibody Ranibizumab In the treatment of 
Neovascular Age-Related Macular Degeneration) Study 
data [9]. Longer treatment data, improved control cohort 
data [20] and societal cost data [21, 22], however, have 
since become available that dramatically alter the patient 
value gain. Financial ROI was not addressed in our 
2008 report [9]. Thus, we believe it important to present 
these data in a cost-utility analysis demonstrating recent 
patient value gain and financial value gain for ranibi-
zumab therapy for AMD. These will be compared with 
2006 data [9] that are available.
Methods
The MARINA and HORIZON trials
The MARINA Trial was a Phase III, 24-month, rand-
omized clinical trial comparing intravitreal ranibizumab 
therapy with a 0.3  mg dose, a 0.5  mg dose, or sham 
therapy for neovascular AMD. The study parameters 
and cost-utility analysis assumptions utilized herein are 
shown in Table 1. We did not analyze 0.3 mg data since 
the 0.5 mg dose was the one approved for use by the Food 
and Drug Administration [5].
At randomization, mean vision in the MARINA Trial 
was 20/80 − 1 in both the 0.5 mg ranibizumab cohort and 
sham control cohort. By the end of 24 months, a mean 22 
intravitreal ranibizumab injections were administered in 
the treatment cohort [1, 9]. At this time, the HORIZON 
(Open-Label Extension Trial of Ranibizumab for Choroi-
dal Neovascularization Secondary to Age-Related Macular 
Degeneration) extension study of the MARINA Trial was 
utilized to model the ranibizumab treatment cohort from 
25 to 48 months, after which a LOCF (last observation car-
ried forward) methodology was used [23]. A mean 3.6 of 
injections were given from months 25 to 48. The timeline of 
the cost-utility model was 12 years, the average life expec-
tancy of a participant in the MARINA Trial [1, 9]. The mean 
visions at different time intervals are shown in Table 2.
Control cohort
Sham cohort, MARINA trial [1], control data were used 
for 24  months, after which MARINA control cohort 
eyes were eligible for treatment with ranibizumab. Thus, 
control data for years 3–12 were derived from the meta-
analysis of Shah and Del Priore [20], who used a dou-
ble reciprocal (Lineweaver-Burke plot) methodology to 
assess the natural course of untreated subfoveal choroidal 
neovascularization associated with AMD. Shah and Del 
Priore plotted the variables of 1/(letters lost) versus 1/
(time in months) (r2 =  .9521) for the control groups of 
six major subfoveal, neovascular, AMD clinical trials [20]. 
The longest follow-up among these trials was 84 months. 
Shah and Del Priore [20] found the pattern of visual loss 
in eyes with subfoveal neovascular AMD to be uniform 
across the trials, with differences arising primarily from 
the time of entry into a trial.
Utilities
The time tradeoff vision utilities utilized herein, as in our 
previous report [9] were obtained with the approval of 
the Wills Eye Hospital Institutional Review Board from 
a cohort of over 1100 interviews of patients with ocu-
lar diseases. The utilities are reproducible and validated 
across age, level of education, ocular diseases, ethnicity, 
gender, income level, and the presence of comorbidities 
[24–31]. The disutilities from adverse events and their 
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associated costs are integrated and treated in the same 
fashion as in our previous report [9].
Costs
Healthcare economic costs can be subdivided into: (1) 
direct medical costs (physician, facility and drug costs), 
(2) direct non-medical costs (caregiver, residence, and 
activities of daily living costs), and (3) indirect costs 
(decreased wages) [14]. In the previous ranibizumab cost-
utility analysis [9] only 2006 U.S. nominal, direct ophthal-
mic medical costs were utilized. The current study uses 
2015 U.S. societal costs in real dollars.
Direct non‑ophthalmic medical costs
Not included previously [9], but included herein, are data 
from Javitt et  al. [21] on Medicare’s excess, direct, non-
ophthalmic medical costs associated with vision loss. These 
costs are attributable to increased depression, injury, SNF 
(skilled nursing facility) admissions, nursing home admis-
sions, and other unexplained Medicare costs. They were 
adjusted to 2015 real dollars using the Medical Care com-
ponent of the Consumer Price Index (CPI) [32]. These costs 
saved by ranibizumab therapy totaled $54,974 (Table 3).
Direct non-ophthalmic medical costs, direct non-med-
ical costs and indirect medical costs only accrue for the 
second-eye model, since the first-eye model, fellow eye 
still has good vision. With Markov modeling (Treeage 
Software Inc., Williamstown, MA) and the data of Bar-
bazetto et  al. [33] 81.3% of the time during the 12-year 
model people have bilateral neovascular AMD (second-
eye model). Thus the societal costs, excluding the direct 
ophthalmic medical costs, were all multiplied by 0.813. 
All direct ophthalmic costs are accrued, whether for the 
first eye or second eye treated.
Table 1 MARINA study clinical and cost-utility analysis parameters
MARINA minimally classic/occult trial of the Anti-VEGF antibody ranibizumab in the treatment of neovascular age-related macular degeneration (AMD), ETDRS early 
treatment diabetic retinopathy study
Clinical features [1]
 Each participant had minimally classic or occult, subfoveal choroidal neovascularization
 Best corrected ETDRS entrance vision in the affected eye: 20/40–20/320
 Choroidal neovascular lesions <12 disc areas at baseline
 Baseline vision: mean 20/80 − 1 in both the ranibizumab treatment and sham treatment cohorts
 Mean baseline age: 77 years
 Treatment protocol: Participants were randomized equally to: (1) a 0.5 mg intravitreal ranibizumab dose cohort (n = 240), (2) a 0.3 mg intravitreal 
ranibizumab dose cohort (n = 238) or (3) a sham injection treatment cohort (n = 238)
 Only data from the 0.5 mg ranibizumab cohort (0.5 mg was the dose eventually approved by the Food & Drug Administration [5]) and the sham 
treatment control cohort were utilized in the cost-utility analysis herein
 The average participant received 22 × 0.05 cc intravitreal injections, given approximately monthly, over 2 years
Cost-utility analysis assumptions
 Mean life expectancy: 12 years for the control and ranibizumab study cohorts [9]
 12-year time span for model utilizing 2-year MARINA data from the sham treatment control group and the 0.05 mg ranibizumab treatment group
 Combined-eye model [14, 15]
 Societal and 3rd party insurer cost perspectives
 Cost basis: average 2015, national, Medicare Fee Schedule
 Vision utilities (based upon visual acuity in the better-seeing eye) [24–31]
 Vision Utility
  20/20 OU 0.97
  20/40 0.80
  20/80 0.701
  20/200 0.62
  20/640 0.538
 Sham treatment, control cohort data utilized: mean vision in MARINA Study for years 1 and 2; Lineweaver-Burke plot meta-analysis [20] control 
cohort for years 3–12
 Treatment cohort (0.5 mg ranibizumab) mean vision: MARINA Study for years 1 and 2, HORIZON open-label extension trial for 25–49 months, LOCF 
(last observation carried forward) for months 49–144 [23]
 Net Present Value (NPV) analysis discounts value outcomes and costs at a 3% annual rate, as per the Panel on Cost-Effectiveness in Health and 
Medicine [13, 18]
 Adverse events as previously listed [9]
 Patient utilities as previously listed [9]
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Direct non‑medical costs
Also absent in the previous report [9], but included herein, 
are the caregiver costs for AMD demonstrated by Schmier 
et al. [22] (Table 3). These were adjusted to 2015 U.S. dol-
lars with the general CPI [22]. Schmier and colleagues [22] 
noted 27.7% of caregivers were paid and 72.3% were unpaid.
Salaries of previously unpaid caregivers freed-up to 
undertake paid employment as a result of ranibizumab 
therapy were treated as direct non-medical costs con-
tributing to a gain in the GDP. The 27.7% of already paid 
caregiver salaries [22] decrease the GDP since these jobs 
are made unnecessary by better vision obtained from 
ranibizumab therapy. While displaced paid caregivers 
can obtain other jobs, we prefer a conservative analysis.
Indirect medical costs
The major, AMD indirect medical cost is loss of patient 
salary. Data from the Americans with Disabilities House-
hold Economic Studies [34] show, between the decreased 
employment rate and decreased salary, a person with 
mild difficulty reading (vision <20/40) has an annual sal-
ary of $22,551, versus $18,915 for a person with severe 
difficult reading and $47,230 for a non-disabled person 
[35]. If a person with severe difficulty reading achieves 
>20/40 vision, the salary gain is ($47,230  −  $18,913=) 
$28,317, while the gain from mild difficulty reading to 
>20/40 vision is ($47,230  −  $22,551=) $24,679. Taking 
into account the proportions of people employed at dif-
ferent ages, the total salary gain from ranibizumab ther-
apy was $9057.
Gross Domestic Product (GDP)
The GDP is a primarily a measure of the final goods and 
services produced within the country in a year [36]. It has 
four components: (1) consumer spending, (2) industry 
investment in new productive capabilities, (3) the excess 
of exports minus imports, and (4) the goods and ser-
vices bought by the government. While a simplistic view, 
increasing the GDP increases the country’s wealth [36].
Net present value analysis
Net present value analysis weighs the costs versus the 
QALY gain, each reduced to present value by discount-
ing. The Panel for Cost-Effectiveness in Health and Medi-
cine [18] has recommended the 3% annual discount rate 
used herein.
Second‑eye, first‑eye and combined‑eye models [9, 37]
The concept of first-eye and second-eye models was 
developed at the Center for Value-Based Medicine® 
based upon data from patients with ocular diseases. The 
first-eye model assumes vision in the fellow eye is nor-
mal; interventional patient value, or benefit, is usually 
not conferred until fellow eye vision deteriorates. The 
second-eye model assumes vision in first eye has already 
deteriorated. Thus, patient value gain is conferred from 
the initiation of therapy. The combined-eye model used 
for our base case is a weighted average of first- and sec-
ond-eye models. Most ocular cost-utility models have 
used the second-eye model [6–12, 15, 17], suggesting a 
bias toward overstatement of patient value gains and 
greater cost-effectiveness.
Table 2 Mean MARINA study vision levels (years 1–2), 
HORIZON extension trial (years 3–4), then last observation 
carried forward to year 12 in the 0.5 mg treatment cohort, 
with a meta-analysis control cohort from years 3–12
Time Control cohort 0.5 mg treatment cohort
Baseline 20/80 − 1 20/80 − 1
6 months 20/100 − 2 20/63
12 months 20/126 20/63 + 1
18 months 20/160 + 2 20/63 + 1
24 months 20/160 − 1.5 20/63 + 1
3 years 20/250 20/63 + 1
4 years 20/320 20/80 + 2
5 years 20/400 20/80 + 1
6 years 20/500 + 2 20/80 + 1
7 years 20/500 20/80 + 1
8 years 20/640 + 2 20/80 + 1
9–12 years 20/640 20/80 + 1
Table 3 societal costs associated with  ranibizumab ther-
apy for neovascular age-related macular degeneration
All costs in 2015 U.S. real dollars, SNF skilled nursing facility
a As per Schmier et al. [22], 27.7% of caregiver costs are paid
Parameter Cost
Direct ophthalmic medical costs
 Ranibizumab therapy (81.3% bilateral) $79,056
Direct non-ophthalmic medical costs
 Injury reduction (−$664)
 Depression reduction (−$2543)
 SNF cost decrease (−$4100)
 Unexplained medical cost decrease (−$28,598)
 Nursing home (−$19,069)
 Total offsetting costs (−$54,974)
 Total direct medical costs $24,082
Direct non-medical costs
 Paid caregiver salariesa (−$82,419)
 Salary gain for freed-up caregivers now able to take up 
gainful employment
(−$215,123)
 Total direct non-medical costs (−$297,542)
Indirect medical costs
 Mean patient wage gain (−$9057)
 Total societal costs (−$282,517)
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Treeage Pro Healthcare, Excel Module 2014 software 
(Treeage Software Inc., Williamstown, MA) was utilized 
to assess the value gain for ranibizumab therapy in the 




With the 12-year combined-eye model, the mean base 
case, patient value gain from intravitreal ranibizumab 
therapy utilizing the meta-analysis control cohort [20] 
from years 3 to 12 was 1.136 QALYs. This converted to 
a mean 16.3% quality-of-life improvement for the aver-
age patient, versus a 10.4% quality-of-life gain in 2006 
[9]. The second-eye model accrued 1.372 QALYs, a 
22.8% improvement in quality-of-life, versus 15.8% in 
2006 [9].
Financial value gain
Direct ophthalmic medical costs
Our previous cost-utility analysis on MARINA 
data utilized a 3rd party insurer (direct ophthalmic 
medical costs) cost perspective with a 2006 average 
national Medicare Fee Schedule cost basis [9]. The 
2006 direct ophthalmic medical cost was $52,652, 
while our comparable cost for the same drug and ser-
vices in 2015 nominal dollars was $46,450, an 11.8% 
decrease since 2006. Adjusting for the Medical Care 
component of the CPI [32], the 2006 real dollar cost 
would be expected to rise to $70,161. Thus, over nine 
years from 2006 to 2015, adjusting with the Medi-
cal Care component of the CPI, the cost of two-year 
ranibizumab therapy in real dollars decreased by 
33.8% (Table  4). Nonetheless, with the addition of 
ranibizumab treatment costs of $8120, simulating the 
HORIZON Trial in years 3 and 4 after baseline [23], 
and mean treatment costs of $24,287 for second eye 
conversion to neovascular AMD over 12  years [33], 
the total direct ophthalmic cost in 2015 is a more 
accurate $79,056.
Direct non‑ophthalmic medical costs (Table 3)
The 12-year direct medical cost saved from the reduction 
of the depression, injury reduction, nursing home, SNF 
and so forth (Table 3) was $54,974 [21]. When this was 
subtracted from the direct ophthalmic medical cost of 
$79,056, the total direct medical cost was $24,082.
Direct non‑medical costs. (Table 3)
The 12-year, direct non-medical cost saving for paid car-
egivers, who comprise 27.7% of caregivers, was $82,419 
(Table  3). The $215,123 for unpaid caregivers corre-
sponded to potential salary earned by freed-up, unpaid 
caregivers obtaining paid jobs [35]. This accrues to soci-
ety and the GDP (Table 3).
Indirect medical costs: increased patient salaries (Table 3)
The 12-year cost associated with higher employment 
rates and improved salaries for ranibizumab-treated neo-
vascular AMD patients with improved vision was $9057.
Total societal costs
The sum of costs accruing against the direct ophthalmic 
medical costs was (−$361,573). When the total direct 
ophthalmic medical cost of $79,056 was subtracted, the 
resultant dollars returned to society (or negative costs), 
primarily patients, was (−$282,517) (Table 3).
Physician fees
Physician fees in 2006 comprised 11.7% of direct ophthal-
mic medical costs and in 2015 comprised 5.6%. Ranibi-
zumab costs in 2006 comprised 85.2% of costs, versus 
91.9% of total costs in 2015 (Table 4).
Gross Domestic Product
The costs which contribute to the GDP are shown in 
Table 5 [36, 37]. Direct ophthalmic medical costs increase 
the GDP, but the direct non-ophthalmic medical costs 
obviated by ranibizumab therapy decrease the GDP. With 
the societal cost perspective, the overall contribution to 
the GDP over the 12 years of the model was $165,842, a 
7.0% annual ROI referent to the $79,056 in direct medi-
cal costs expended for ranibizumab therapy. With the 
3rd party insurer cost perspective, there was a negative 
Table 4 2006 Versus 2015 direct ophthalmic medical 
costs and  patient value gain versus  ranibizumab therapy 
for first two years
Parentheses indicate percent of total direct ophthalmic medical costs. NA not 
applicable. Note that patient value gain = quality-of-life gain
Cost 2006 2015
Physician $6167 (11.7%) $2611 (5.6%)
Ranibizumab $44,812 (85.2%) $42,665 (91.9%)
Diagnostic tests $1230 (2.3%) $1174 (2.5%)
Post-operative antibiotics $414 (0.8%) $0 (0.0%)
Total $52,652 (100%) $46,450 (100%)
Adjusted with medical CPI to 2015 
US $
$70,161 $46,450
Decrease in real dollars from 2006 
to 2015
NA −33.8%
Patient value (quality-of-life) gain 2006 2015
First-eye model 6.4% 9.8%
Second-eye model 15.8% 22.8%
Combined-eye model 10.4% 16.3%
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ROI for the direct ophthalmic medical costs expended 
(Table 5).
Cost‑utility analysis
An average cost-utility analysis compares an intervention 
to no therapy, while an incremental cost-utility analysis 
compares an intervention to other interventions [14].
Average CUR
The average, combined-eye, CUR with the MARINA 
Study societal cost perspective was (−$282,517/1.163=) 
(−243,921/QALY) (Table  5). A negative CUR indicates 
a dominant therapy in that it is less expensive than the 
alternative (observation) and at the same time it gener-
ates greater patient value than the alternative (obser-
vation herein). The CUR associated with the 3rd party 
insurer cost perspective using all direct medical costs 
(ophthalmic  +  non-ophthalmic) was ($24,082/1.136=) 
$21,199/QALY. With direct ophthalmic medical costs 
alone, the CUR was ($79,056/1.136=) $69,591/QALY. 
While the latter costs for NVAMD therapy over 12 years 
were higher than in 2006 [9], the earlier model did not 
include HORIZON trial and fellow eye treatment costs.
Incremental CURs
Incremental CURs are calculated from Value-Based 
Medicine®, published cost-utility data [15, 17] using a 3rd 
party insurer cost perspective (Table 6). The incremental 
CUR for ranibizumab therapy for NVAMD versus laser 
therapy was $20,643/QALY, while that referent to intra-
vitreal pegaptanib was $3546/QALY and for photody-
namic therapy was $16,044/QALY, all very cost-effective.
Sensitivity analysis
The sensitivity analyses were performed using the soci-
etal cost perspective, average cost-utility, and a 3% annual 
discount rate unless otherwise indicated (Table 7).
Eye models
The societal cost perspective, first-eye model conferred 
0.680 QALY, a 9.8% improvement in quality-of-life, while 
the second-eye model conferred 1.372 QALYs, a 22.8% 
Table 5 Societal and  3rd party insurer cost perspective cost-utility analyses (2015 U.S. real dollars discounted at  3% 
annually)
Costs in parentheses () are negative costs, indicating they are accrued against the direct ophthalmic medical costs of ranibizumab therapy
MARINA minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular age-related macular degeneration (AMD) [9], VRQOL 
vision-related quality-of-life, 3rd party insurer third party insurer cost perspective utilizing the direct ocular medical costs and the direct non-ophthalmic medical costs
ROI return-on-investment, QALY quality-adjusted life-year, $/QALY dollars expended per QALY gained, gained, VRQOL vision-related quality-of-life
a Costs adding to the Gross Domestic Product (GDP)
 b Costs subtracting from the Gross Domestic Product
Cost perspective Societal 3rd party insurer
Ranibizumab therapy, direct ocular medical costsa 79,056 79,056
Depressionb (2543) (2543)
Injuryb (664) (664)
Subacute Nursing Facility (SNF)b (4100) (4100)
Nursing homeb (19,046) (19,046)
Unexplained direct medical Medicare costsb (28,598) (28,598)
Patient employment gaina (9057) –
Paid caregivers released from jobsb (82,419) –
Increased paid employment by freed-up unpaid caregiversa (215,123) –
Total costs offsetting the direct ophthalmic medical costs (361,573) (54,974)
Direct medical costs + offsetting costs = financial return to society 282,517 (24,082)
Financial ROI for direct ophthalmic medical costs expended 14.7% −3.5%
QALY gain: combined-eye model 1.136 1.136
QALY gain: second-eye model 1.372 1.372
VRQOL gain, combined-eye model 16.3% 16.3%
VRQOL gain, second-eye model 22.8% 22.8%
$/QALY, combined-eye model (242,921) 20,707
$/QALY, second-eye model (205,916) 17,552
Addition to GDP 165,842 24,082
Financial ROI for GDP referent to direct ophthalmic medical costs expended 7.0% −11.4%
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improvement in quality-of-life. The first-eye model, soci-
etal, CUR was (−$415,367)/QALY, while the second-eye 
model, societal, CUR was (−$205,971)/QALY. Since the 
costs were the same with each of these three variants, a 
less negative CUR indicates greater cost-effectiveness. In 
general, however negative CURs are not comparable, but 
rather indicate dominance.
Changes in cost
Increasing ranibizumab costs by 100%, the combined-
eye, adding four additional ranibizumab injections 
annually and excluding caregiver costs all yielded cost-
effective results (Table 7). Using costs from a treat-and-
extend model [38], the 3rd party insurer cost perspective 
had a CUR of $45,995, similar to that of $48,036 using 
comparable costs in our current analysis.
Value gain
When the QALY gain decreased by 50% from years 5 to 
12, the CUR was (−$462,960/QALY).
$50,000/QALY
For a societal cost perspective CUR of $50,000/QALY, 
the direct ophthalmic medical costs had to be increased 
to $339,317, a 329% increase over the current $$79,056. 
For a CUR of $100,000/QALY, the direct ophthalmic 
Table 6 Incremental cost-utility ratios of ranibizumab ref-
erent to  laser photocoagulation, intravitreal pegaptanib, 
and PDT
All cost-utility analyses in this table use patient utilities, a 3rd party insurer cost 
perspective and 2nd-eye model. PDT photodynamic therapy with verteporfin, 
QALY dollars expended per quality-adjusted life year gained, or cost-utility ratio, 
Avr. $/QALY average cost-utility ratio, Incr. NA not applicable, ranib. ranibizumab 
therapy. All outcomes and costs are discounted at 3% annually
a Incremental cost-utility ratio of ranibizumab referent to the other 
interventions
Intervention QALY gain Cost Avr. $/QALY Incr. $/QALYa
Ranibizumab, 2015 1.372 $24,082 $17,552 NA
Laser 0.25717 $1071 $6157 $20,643
Pegaptanib, intra-
vitreal
0.83417 $22,175 $26,589 $3546
PDT 0.74715 $14,057 $18,818 $16,044
Table 7 Sensitivity analysis results for ranibizumab for the treatment of subfoveal neovascular AMD utilizing a societal 
cost perspective, average cost-utility analysis (bilateral treatment model unless otherwise specified)
Parentheses () negative dollars and negative cost-utility ratios, QALY quality-adjusted life year, QOL quality-of-life, $/QALY cost-utility ratio, or dollars expended per 
QALY gained. Note that a negative cost-utility ratio simply means that ranibizumab therapy dominates sham therapy in that it confers greater patient value and is less 
expensive
a Ranibizumab injections [38] = year 1—7.6, year 2—5.7, year 3—5.8, year 4—1.8, year 5 forward—none
Interventional variables QALY/QOL gain Cost $/QALY
Eye model
 2nd eye model, societal costs 1.372/22.8% (−$282,517) (−$205,971)
 2nd eye model, 3rd party insurer costs 1.372/22.8% $24,082 $17,557
 1st eye model, societal costs 0.680/9.8% (−$282,517) (−$415,367)
 1st eye model, 3rd party insurer costs 0.680/9.8% $24,082 $35,406
 Combined-eye model, societal costs—BASE CASE 1.136/16.3% (−$282,517) (−$248,639)
 Combined-eye model, all 3rd party insurer costs 1.136/16.3% $24,082 $21,194
 Combined-eye model, direct ophthalmic medical costs only 1.136/16.3% $79,056 $69,592
Costs
 Ranibizumab cost increased 100% 1.136/16.3% (−$233,271) (−$205,344)
 Four additional ranibizumab annually, years 3–13 1.136/16.3% (−$213,910) (−$188,301)
 Caregiver costs excluded 1.136/16.3% $15,025 $13,226
 Cost of therapy decreased by 50% 1.136/16.3% (−$322,045) (−$283,490)
Treat-and-extend regimen costs (assuming same value gain) [38]a
 Direct ophthalmic medical costs only, treat-and- extend, no fellow eye treatment costs 1.136/16.3% $52,250 $45,995
 Current study, direct ophthalmic medical costs, no fellow eye treatment costs 1.136/16.3% $54,569 $48,036
Value gain
 Patient value gain (QALY gain) drops by 50% for years 5–12, societal costs 0.688/9.9% (−$282,517) (−$410,757)
 Patient value gain (QALY gain) drops by 50% years 5–12, 3rd party insurer costs 0.688/9.9% $24,082 $35,013
Cost-utility
 For cost-utility of $50,000/QALY 1.136/16.3% $56,800 $50,000
 For cost-utility of $100,000/QALY 1.136/16.3% $113,600 $100,000
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medical costs had to be increased to $432,021, a 401% 
increase over $79,056.
Comparisons
A comparison of patient value conferred by other drug 
classes, using a similar cost-utility model, shows the 
considerable value gain from ranibizumab therapy. Data 
from the Center for Value-Based Medicine® are shown 
in Table  8 [13, 16, 37, 39, 40]. Among the drug groups, 
only anti-depressants, β-blockers for glaucoma, and pro-
ton pump inhibitors match or exceed the patient value 
gain conferred by ranibizumab therapy for NVAMD. 
Ranibizumab value gain far exceeds that conferred by 
interventions for systemic arterial hypertension, hyper-




Our analysis demonstrates that ranibizumab therapy for 
NVAMD confers considerable patient value. This does 
not refer to cost, but rather the improvement in quality-
of-life conferred by ranibizumab. Our previous analysis 
of patient value gain for the same intervention [9] dem-
onstrated a 10.4% combined-eye model, value gain [9], 
versus 16.3% in the current analysis. With HORIZON 
Table 8 Patient value conferred by drug classes across medicine [16, 37]
All values are from the Center for Value-Based Medicine Pharmaceutical Value Index database©
SSRI selective serotonin reuptake inhibitor, statins HMG-CoA reductase inhibitors
Drug class Indication # of drugs Patient value 
gain (%)
Histamine H-1 receptor antagonists, oral Seasonal allergy 10 4–7
Histamine H-1 receptor antagonists, topical ocular Allergy, ocular 6 0.1–9.9
SSRI drugs Depression, major 5 20–23
Anti-depressants, non-SSRI Depression, major 6 21–32
cGMP-specific phosphodi-esterase inhibitors Erectile dysfunction 3 2.7–2.9
Proton pump inhibitors Acute erosive esophagitis 5 13–26
Proton pump inhibitors Gastroesophageal reflux 5 8–14
Proton pump inhibitors Zollinger-Ellison Syndrome 5 29–38
Histamine H-2 receptor antagonists Acute erosive esophagitis 4 5–11
Histamine H-2 receptor antagonists Gastroesophageal reflux 4 3–7
B-blockers, topical Glaucoma 3 16–19
Statins Hyperlipidemia 6 3–5
Diuretics Hypertension, systemic arterial 5 7.7–9.4
ACE inhibitors Hypertension, systemic arterial 9 6.5–9.1
B-blockers, oral Hypertension, systemic arterial 7 6.3–9.1
Hypnotics Insomnia 7 1.2–8.8
Ranibizumab, combined eye model Neovascular age-related macular degeneration, 
current study
1 16.3
Bisphosphonates Osteoporosis 3 0.8–1.1
α1-adrenergic blockers Prostatic hyperplasia 3 0.6–1.4
Table 9 Macroeconomic (ROI) for  ranibizumab therapy for  neovascular AMD using the societal cost perspective, com-
bined-eye model
ROI return-on-investment referent to the direct medical costs associated with ranibizumab administration, GDP Gross Domestic Product, MARINA minimally classic/
occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular age-related macular degeneration (AMD)
Cost perspective Direct ophthalmic  
medical cost  
per patient
Annual # of  
cases
Total direct ophthalmic  
medical costs
Net cost/case with  





MARINA—costs off-setting the s 
direct ocular medical costs
$79,056 178,000 $14.1 billion (−$282,517) $50.2 billion
MARINA GDP gain $79,056 178,000 $14.1 billion (−$165,842) $29.5 billion
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trial data [23] and control cohort data from Shah and 
DelPriore [20], our 2015 analysis provides more reliable 
data than our 2006 data [9], which used a LOCF meth-
odology from month 25 forward. It should be noted that 
ophthalmic patient utility gains tend to be similar in the 
United States, Canada and Europe [14, 24, 41, 42]. Utili-
ties appear to be innate to human nature rather than 
one society [14]. Thus, the patient value gain data in this 
analysis can be integrated with the associated costs for 
ranibizumab therapy for NVAMD in another country 
and likely provide a valid cost-utility analysis for that 
country.
Costs
As used in the MARINA Study [1], intravitreal ranibi-
zumab therapy yields a considerable financial return-
on-investment to society and the GDP. The GDP is often 
regarded as a determinant of a nation’s wealth [36]. 
Ranibizumab therapy improves physical well-being, or 
human capital, which directly results in financial capi-
tal gain and also allows a dramatic decrease in caregiver 
costs.
The societal costs associated with many healthcare 
interventions are not well-defined, and only recently have 
those associated with vision loss and macular degenera-
tion been identified [22, 23, 37, 39, 40, 43]. The majority 
of cost-utility analyses have not included caregiver costs, 
but they are especially relevant for untreated bilateral 
NVAMD [23].
Concerning employment and the decreased salary 
associated with disabilities, Americans with Disabilities 
Household Economic Studies data from the U.S. Cen-
sus Bureau [34] are enlightening. Those with difficulty 
reading have lower mean earnings than those with 
hearing difficulty, a learning disability or in a wheel-
chair [34].
Cost‑utility
The societal cost perspective generally produces an 
improved CUR for an intervention compared to the 
direct ophthalmic medical cost perspective [9, 37, 40]. 
This concept is demonstrated herein for ranibizumab 
(Table  5). Caregiver costs saved, improved salary and 
employment and direct medical costs obviated (depres-
sion, injury, facility admissions etc.) herein all accrue 
against the direct ophthalmic medical costs expended.
Cost‑effectiveness standards
Healthcare interventions costing <$100,000/QALY are 
generally accepted as cost-effective in the U.S. [44] The 
World Health Organization [45] suggests an upper cost-
effectiveness limit of 3× GDP per capita, or ~$164,000/
QALY for the United States [46]. The use of ranibizumab 
in the societal cost perspective is very cost-effective by 
each of these criteria.
Potential study weaknesses
As with any analysis, there are potential inherent weak-
nesses in this study.
Neovascular AMD sub‑types
The MARINA clinical trial assessed occult and mini-
mally classic AMD variants, which together comprise 
80% of neovascular AMD cases [47]. Ranibizumab 
therapy for classic neovascular AMD (20% of cases), 
as studied in the ANCHOR clinical trial [3], results in 
slightly greater, patient value gain than in the MARINA 
trial [1], suggesting the data in our analysis are actually 
conservative.
Absence of long‑term clinical trial data
The absence of randomized clinical trial data after two 
years is a drawback, through HORIZON data provide 
treatment efficacy thru 48  months and Shah and DelP-
riore provide an excellent long-term control cohort [20]. 
The SEVEN-UP Study [48] followed ranibizumab-treated 
NVAMD patients for up to seven years, but the very 
small numbers of patients (~10% of those enrolled) likely 
introduce bias. Thus, we did not employ these data. The 
sensitivity analysis, however, demonstrates excellent cost-
effectiveness even if ranibizumab loses 50% of its efficacy 
from months 49 to 144.
Unpaid caregiver costs
Unpaid caregivers may not obtain paid employment once 
freed-up to do so, but the sensitivity analysis addressed 
this as well. Even when all costs related to unpaid caregiv-
ers gaining paid employment are excluded, the CUR is 
still very cost-effective at $13,226/QALY.
Use of other drugs
Our intent herein was to compare the changes in pref-
erence-based comparative effectiveness and cost-utility 
for the same drug treating the same disease over a near 
decade. We thus did not perform cost-utility analy-
ses on other VEGF inhibitors used for the treatment of 
NVAMD, such as aflibercept and bevacizumab.
Study strengths: differences from 2006 to 2015
Our paper utilized patient utilities and standardized 
VBM format [14]. In addition, four major changes were 
integrated into the current study that differentiate the 
results from our 2006 study costs [9]. These include: (1) 
a more reliable control cohort from Shah and DelPriore 
[20], (2) HORIZON extension trial treatment data [23], 
(3) societal costs from the studies of Javitt [21], Schmier 
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[22] and Steinmetz [34], and (4) costs associated with 
the conversion of fellow eyes with atrophic AMD to 
NVAMD over the 12-year model time frame [33]. We 
are unaware that these unique parameters have been 
used together by other authors for assessing the cost-
effectiveness of neovascular AMD therapy, especially in 
conjunction with primary utilities obtained from over 
1100 ophthalmic patients. We believe they create a much 
more robust model than those used previously for the 
cost-effectiveness associated with treatment of NVAMD. 
As advances occur in healthcare interventions, they also 
take place in the economic evaluation of interventions. 
In this regard, it can be seen that a one-year cohort of 
178,000 new neovascular AMD cases [49, 50] treated 
with ranibizumab will return over $50 billion to society 
over a 12-year period (Table 9).
Conclusions
In summary, the 2015 patient value gain conferred by, 
and costs associated with, ranibizumab therapy for 
NVAMD compare favorably with those from 2006. 
Longer-term treatment cohort follow-up, a more reli-
able control cohort, the inclusion of societal costs and 
a bilateral treatment model all result in a more robust 
2015 analysis. The therapy provides great patient value 
than many common interventions across healthcare and 
also provides a considerable financial return-on-invest-
ment to society Changing patterns of therapy, such as 
increased use of a treat-and-extend model may result in 
more favorable cost-effectiveness yet for ranibizumab 
therapy.
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